	US 12,409,208 B2
	Treating tissue fibrosis with interleukin 24
Ming-Shi Chang, Tainan (TW)
Assigned to LBL BIOTECHNOLOGY INC., Tainan (TW)
Appl. No. 17/771,930
Filed by LBL BIOTECHNOLOGY INC., Tainan (TW)
PCT Filed Oct. 28, 2020, PCT No. PCT/US2020/057781 § 371(c)(1), (2) Date Apr. 26, 2022, PCT Pub. No. WO2021/086997, PCT Pub. Date May 6, 2021.
Claims priority of provisional application 62/926,884, filed on Oct. 28, 2019.
Prior Publication US 2022/0378875 A1, Dec. 1, 2022
Int. Cl. A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 11/00 (2006.01)

CPC A61K 38/20 (2013.01) [A61K 39/3955 (2013.01); A61P 11/00 (2018.01); A61K 2039/505 (2013.01)]

11 Claims

1. A method for alleviating or delaying the onset of or treating a tissue fibrosis occurred in kidney or lung, the method comprising administering an effective amount of an interleukin 24 (IL-24) protein to a subject in need thereof,

wherein the IL-24 protein is a human IL-24 protein.